Fluidda (Los Angeles) said today that the FDA has cleared its Broncholab software designed to to assist in diagnosing and monitoring of respiratory diseases for clinical use.
The Broncholab platform can provide a number of functional respiratory imaging (FRI) parameters to physicians via an online platform, according to the company. FRI combines high-resolution computed tomography, computational fluid dynamics and artificial intelligence technology.
Compared with conventional lung-function tests such as spirometry, techniques such as FRI yield more accurate regional information that is clinically relevant for early and correct diagnosis, according to Fluidda.
“Functional respiratory imaging has been used in clinical trials for many years and has proven its value time and time again,” said Fluidda CEO Dr. Jan De Backer in a news release. “Broncholab now extends these capabilities into clinical practice, which is a tremendous step forward in our quest for better respiratory care. We are living in a time where respiratory viruses cause significant disruption to daily life with high associated cost. We are striving to better understand respiratory illnesses with our novel technology to be more prepared for the next viral outbreak and to deal with the increased number of patients with lung diseases worldwide.”